RARE DISEASE
Indolent B-cell non-Hodgkin lymphoma
Indolent B-cell non-Hodgkin lymphoma
Indolent B-cell non-Hodgkin lymphoma
Synonyms: Indolent B-cell NHL
Synonyms: Indolent B-cell NHL
Synonyms: Indolent B-cell NHL
Drug discovery
2
drugs
With orphan designations
Overview
Indolent B-cell non-Hodgkin lymphomas (NHLs) are slow-growing malignancies comprising ~40% of NHL cases, including follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma [1][6][16]. Median age at diagnosis is 68, with a 5-year survival rate of 74% [2][5]. Though often asymptomatic initially, these lymphomas are incurable and may transform into aggressive subtypes. Management spans observation (watch-and-wait) for asymptomatic cases to rituximab-based chemoimmunotherapy, targeted agents, and CAR T-cell therapy for advanced/relapsed disease [1][3][8][13].
Burden
Chronic course: Median survival ≈12–14 years, with frequent relapses [11][12].
Leading to 8th highest cancer mortality (5.0 deaths/100,000/year) [2][6].
High healthcare utilization due to lifelong monitoring, treatment-related toxicity risks, and ~20–30% risk of transformation to aggressive NHL (e.g., DLBCL) [6][15][16].
Therapies
First-line: Observation, localized radiation, or rituximab ± chemotherapy (e.g., R-CVP, R-CHOP, bendamustine-rituximab) [1][3][8].
Relapsed/refractory: BTK inhibitors (zanubrutinib), EZH2 inhibitors (tazemetostat), bispecific antibodies (mosunetuzumab), and CAR T-cell therapy [1][6][13].
Maintenance: Rituximab every 2–3 months for 2 years post-remission [1][8].
Categories: rare hematological diseases, rare neoplastic diseases, rare transplant-related disorders
Research Papers
889 drug discovery papers related to Indolent B-cell non-Hodgkin lymphoma, with 3 first-in-class and 15 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
889 drug discovery papers related to Indolent B-cell non-Hodgkin lymphoma, with 3 first-in-class and 15 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-08 | Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Tetraspanin CD37, highly expressed in mature B-cells, represents an opportunity for therapeutic targeting in B-cell malignancies. GEN3009 (DuoHexaBody-CD37), a humanized biparatopic IgG1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overlapping CD37 epitopes, was shown to induce potent tumor cell killing through enhanced complement-dependent cytotoxicity (CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo. GEN3009 was assessed in non-clinical studies and a phase 1 dose-escalation study of B-cell non-Hodgkin's lymphoma (B-NHL). After a non-clinical toxicity study was conducted in cynomolgus monkeys, a phase 1, first-in-human, open-label, multicenter dose-escalation trial of GEN3009 monotherapy enrolled adults with relapsed/refractory (R/R) B-NHL (NCT04358458). A modified Bayesian optimal interval design informed dose escalation and de-escalation with dose levels ranging from 6 mg to 2000 mg. Primary endpoints were the rate of dose-limiting toxicities (DLTs) to determine the recommended phase 2 dose (RP2D) and safety and tolerability. In the toxicity study, 10 mg/kg GEN3009 weekly was identified as the highest non-severely toxic dose. In the phase 1 study, from March 13, 2020, to July 28, 2023, 46 patients with R/R B-NHL received intravenous GEN3009 infusions. Median duration of treatment was 1.2 months (range, 0.0-14.5). No DLTs were observed up to 1600 mg. The most common treatment-emergent adverse events were neutropenia (n=41 (89.1%)), infusion-related reactions (n=39 (84.8%)), and thrombocytopenia (n=18 (39.1%)). Plasma GEN3009 concentrations increased over time with increasing GEN3009 doses, with no apparent accumulation of GEN3009 observed over the course of treatment. Antitumor activity was observed at dose levels of ≥180 mg in both aggressive and indolent NHL. GEN3009 treatment reduced total hemolytic complement activity (CH50) levels in serum, and peak changes in CH50 levels were significantly correlated with clinical response (p=0.008 by Wilcoxon rank-sum test). Based on safety, efficacy, and pharmacokinetics, the RP2D of GEN3009 was determined to be 1200 mg. Preliminary data suggest that GEN3009 monotherapy demonstrated an acceptable safety profile at the RP2D of 1200 mg, with modest clinical activity. These findings provide the first clinical proof-of-concept for hexamerization-potentiated molecules that induce antitumor activity through enhanced CDC.
2026-07-07 | Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.
Epcoritamab is a CD3 × CD20 T-cell-engaging bispecific antibody approved for the treatment of various types of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) and R/R follicular lymphoma (FL), after at least two lines of systemic therapy. Here, we develop and calibrate repeated time-to-event models to assess the impact of optimized step-up dosing (SUD) regimens and the effect of intravenous fluids and/or corticosteroids on cytokine release syndrome (CRS) risk. The analysis used pooled data from 600 patients with aggressive non-Hodgkin lymphoma (aNHL) and indolent NHL (iNHL) who received subcutaneous epcoritamab in 28-day cycles in the EPCORE® NHL-1 and EPCORE® NHL-3 studies (NCT03625037, NCT04542824). In the calibrated model, prior CAR T cell therapy (125/600 patients [20.8%]) was associated with a 69.7% reduction (95% confidence interval [CI], 38.2-85.2) in the maximum stimulatory effect of epcoritamab on the hazard of Grade ≥2 CRS. Intravenous fluids or dexamethasone during Cycle (C)1 were associated with a 2.89-fold (95% CI, 1.57-5.30) increase in the half-maximal effective plasma concentration of epcoritamab on stimulation (S50). Furthermore, prophylaxis with intravenous fluids and dexamethasone during C1 was associated with a 3.79-fold (95% CI, 1.65-8.73) increase in S50. Simulations show that the use of dexamethasone further reduces Grade ≥2 CRS risk compared with prednisone in patients with aNHL/iNHL. Moreover, a 3-SUD design further reduces CRS risk in patients with iNHL. Overall, our models showed that the approved 2-SUD regimen for R/R LBCL and 3-SUD regimen for R/R FL-together with intravenous fluids and dexamethasone prophylaxis-are adequate to reduce Grade ≥2 CRS risk.
2026-07-05 | Efficacy and safety of CD19 CAR T-cell therapy in relapsed/refractory follicular lymphoma: A systematic review and meta-analysis.
Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma characterized by frequent relapses despite initial responsiveness to chemoimmunotherapy. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has shown promising efficacy in relapsed or refractory disease, though safety concerns such as cytokine release syndrome (CRS) and neurological events remain. This study aimed to evaluate the efficacy and safety of CD19 CAR T-cell therapy in relapsed or refractory FL. A comprehensive search using six databases, including PubMed, Scopus, and Embase, was performed to identify relevant studies. Data on overall response rate (ORR), complete response rate (CRR), progression-free survival (PFS), duration of response (DOR), overall survival (OS), and adverse events, including CRS and neurological events, were extracted. Pooled estimates were calculated using the quality effects model. This review was registered in PROSPERO (CRD420251133655). Out of 2303 records initially identified, 6 studies met the inclusion criteria. The pooled efficacy analysis demonstrated an ORR of 93.5% (95% CI: 86.3-98.3%) and a CRR of 84.5% (95% CI: 72.6-93.6%). Regarding safety outcomes, the pooled estimate for CRS of any grade was 61.4% (95% CI: 45.0-76.6%). For neurological events, it was 33.6% (95% CI: 13.4-57.1%). Subgroup analyses identified prior therapy lines and CAR construct design as sources of heterogeneity. In conclusion, CD19 CAR T-cell therapy demonstrates high efficacy with a generally acceptable safety in relapsed or refractory FL, supporting its consideration for patients with limited treatment options while highlighting the need for further research on long-term outcomes.
2026-07-08 | Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Tetraspanin CD37, highly expressed in mature B-cells, represents an opportunity for therapeutic targeting in B-cell malignancies. GEN3009 (DuoHexaBody-CD37), a humanized biparatopic IgG1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overlapping CD37 epitopes, was shown to induce potent tumor cell killing through enhanced complement-dependent cytotoxicity (CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo. GEN3009 was assessed in non-clinical studies and a phase 1 dose-escalation study of B-cell non-Hodgkin's lymphoma (B-NHL). After a non-clinical toxicity study was conducted in cynomolgus monkeys, a phase 1, first-in-human, open-label, multicenter dose-escalation trial of GEN3009 monotherapy enrolled adults with relapsed/refractory (R/R) B-NHL (NCT04358458). A modified Bayesian optimal interval design informed dose escalation and de-escalation with dose levels ranging from 6 mg to 2000 mg. Primary endpoints were the rate of dose-limiting toxicities (DLTs) to determine the recommended phase 2 dose (RP2D) and safety and tolerability. In the toxicity study, 10 mg/kg GEN3009 weekly was identified as the highest non-severely toxic dose. In the phase 1 study, from March 13, 2020, to July 28, 2023, 46 patients with R/R B-NHL received intravenous GEN3009 infusions. Median duration of treatment was 1.2 months (range, 0.0-14.5). No DLTs were observed up to 1600 mg. The most common treatment-emergent adverse events were neutropenia (n=41 (89.1%)), infusion-related reactions (n=39 (84.8%)), and thrombocytopenia (n=18 (39.1%)). Plasma GEN3009 concentrations increased over time with increasing GEN3009 doses, with no apparent accumulation of GEN3009 observed over the course of treatment. Antitumor activity was observed at dose levels of ≥180 mg in both aggressive and indolent NHL. GEN3009 treatment reduced total hemolytic complement activity (CH50) levels in serum, and peak changes in CH50 levels were significantly correlated with clinical response (p=0.008 by Wilcoxon rank-sum test). Based on safety, efficacy, and pharmacokinetics, the RP2D of GEN3009 was determined to be 1200 mg. Preliminary data suggest that GEN3009 monotherapy demonstrated an acceptable safety profile at the RP2D of 1200 mg, with modest clinical activity. These findings provide the first clinical proof-of-concept for hexamerization-potentiated molecules that induce antitumor activity through enhanced CDC.
2026-07-07 | Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.
Epcoritamab is a CD3 × CD20 T-cell-engaging bispecific antibody approved for the treatment of various types of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) and R/R follicular lymphoma (FL), after at least two lines of systemic therapy. Here, we develop and calibrate repeated time-to-event models to assess the impact of optimized step-up dosing (SUD) regimens and the effect of intravenous fluids and/or corticosteroids on cytokine release syndrome (CRS) risk. The analysis used pooled data from 600 patients with aggressive non-Hodgkin lymphoma (aNHL) and indolent NHL (iNHL) who received subcutaneous epcoritamab in 28-day cycles in the EPCORE® NHL-1 and EPCORE® NHL-3 studies (NCT03625037, NCT04542824). In the calibrated model, prior CAR T cell therapy (125/600 patients [20.8%]) was associated with a 69.7% reduction (95% confidence interval [CI], 38.2-85.2) in the maximum stimulatory effect of epcoritamab on the hazard of Grade ≥2 CRS. Intravenous fluids or dexamethasone during Cycle (C)1 were associated with a 2.89-fold (95% CI, 1.57-5.30) increase in the half-maximal effective plasma concentration of epcoritamab on stimulation (S50). Furthermore, prophylaxis with intravenous fluids and dexamethasone during C1 was associated with a 3.79-fold (95% CI, 1.65-8.73) increase in S50. Simulations show that the use of dexamethasone further reduces Grade ≥2 CRS risk compared with prednisone in patients with aNHL/iNHL. Moreover, a 3-SUD design further reduces CRS risk in patients with iNHL. Overall, our models showed that the approved 2-SUD regimen for R/R LBCL and 3-SUD regimen for R/R FL-together with intravenous fluids and dexamethasone prophylaxis-are adequate to reduce Grade ≥2 CRS risk.
2026-07-05 | Efficacy and safety of CD19 CAR T-cell therapy in relapsed/refractory follicular lymphoma: A systematic review and meta-analysis.
Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma characterized by frequent relapses despite initial responsiveness to chemoimmunotherapy. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has shown promising efficacy in relapsed or refractory disease, though safety concerns such as cytokine release syndrome (CRS) and neurological events remain. This study aimed to evaluate the efficacy and safety of CD19 CAR T-cell therapy in relapsed or refractory FL. A comprehensive search using six databases, including PubMed, Scopus, and Embase, was performed to identify relevant studies. Data on overall response rate (ORR), complete response rate (CRR), progression-free survival (PFS), duration of response (DOR), overall survival (OS), and adverse events, including CRS and neurological events, were extracted. Pooled estimates were calculated using the quality effects model. This review was registered in PROSPERO (CRD420251133655). Out of 2303 records initially identified, 6 studies met the inclusion criteria. The pooled efficacy analysis demonstrated an ORR of 93.5% (95% CI: 86.3-98.3%) and a CRR of 84.5% (95% CI: 72.6-93.6%). Regarding safety outcomes, the pooled estimate for CRS of any grade was 61.4% (95% CI: 45.0-76.6%). For neurological events, it was 33.6% (95% CI: 13.4-57.1%). Subgroup analyses identified prior therapy lines and CAR construct design as sources of heterogeneity. In conclusion, CD19 CAR T-cell therapy demonstrates high efficacy with a generally acceptable safety in relapsed or refractory FL, supporting its consideration for patients with limited treatment options while highlighting the need for further research on long-term outcomes.
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Indolent B-cell non-Hodgkin lymphoma.
2 orphan drug designations for Indolent B-cell non-Hodgkin lymphoma.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
blinatumomab | antibodies | FDA | 2006-02-06 | — | Amgen, Inc. |
Cladribine [Litak] | small molecules | EMA | 2001-09-18 | — | Lipomed GmbH |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.